D L Forrest
Overview
Explore the profile of D L Forrest including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
246
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liu X, Rothe K, Yen R, Fruhstorfer C, Maetzig T, Chen M, et al.
Leukemia
. 2017 Apr;
31(11):2376-2387.
PMID: 28366933
Tyrosine kinase inhibitor (TKI) therapies induce clinical remission with remarkable effects on chronic myeloid leukemia (CML). However, very few TKIs completely eradicate the leukemic clone and persistence of leukemic stem...
2.
Laneuville P, Barnett M, Belanger R, Couban S, Forrest D, Roy D, et al.
Curr Oncol
. 2012 Jul;
13(6):201-21.
PMID: 22792021
Chronic myelogenous leukemia (cml) is a disease characterized by the expression of Bcr/Abl, an oncogenic protein tyrosine kinase, and by evolution over time from a relatively benign chronic phase to...
3.
Abou-Mourad Y, Lau B, Barnett M, Forrest D, Hogge D, Nantel S, et al.
Bone Marrow Transplant
. 2009 Jul;
45(2):295-302.
PMID: 19597425
We analyzed the late outcomes of 429 long-term survivors post allogeneic hematopoietic SCT (allo-HSCT) who received transplant in our center between 1981 and 2002, and were free of their primary...
4.
Ramadan K, Connors J, Al-Tourah A, Song K, Gascoyne R, Barnett M, et al.
Bone Marrow Transplant
. 2008 Aug;
42(9):601-8.
PMID: 18695664
Outcome is poor with conventional therapy for relapsed transformed non-Hodgkin's lymphoma (NHL). Autologous SCT has been successfully employed; however the impact of allogeneic SCT has not been well defined. We...
5.
Nevill T, Hogge D, Toze C, Nantel S, Power M, Abou Mourad Y, et al.
Bone Marrow Transplant
. 2008 Aug;
42(10):659-66.
PMID: 18679372
Administration of alkylating agents (Alk), topoisomerase II inhibitors (Topo II) and radiotherapy (RT) can result in therapy-related myelodysplastic syndrome or acute myelogenous leukaemia (t-MDS/t-AML), the optimal treatment for which is...
6.
Forrest D, Jiang X, Eaves C, Smith C
Curr Oncol
. 2008 May;
15(2):90-7.
PMID: 18454182
Chronic myeloid leukemia (cml) is a myeloproliferative disorder whose therapy has changed dramatically since the late 1990s. With the introduction of the tyrosine kinase inhibitor (tki) imatinib mesylate, the treatment...
7.
Halim T, Song K, Barnett M, Forrest D, Hogge D, Nantel S, et al.
Ann Oncol
. 2007 Apr;
18(7):1246-52.
PMID: 17442662
Background: Curative intent chemotherapy for acute myelogenous leukemia (AML) leads to prolonged severe neutropenia, during which patients are highly susceptible to infection. Traditionally these high-risk patients were treated as inpatients....
8.
Song K, Barnett M, Gascoyne R, Chhanabhai M, Forrest D, Hogge D, et al.
Ann Oncol
. 2006 Dec;
18(3):535-40.
PMID: 17158775
Background: Controversy exists regarding the role of high-dose therapy followed by stem-cell transplant (SCT) in the treatment of T-cell lymphoblastic lymphoma (T-LBL). We conducted an intention-to-treat analysis of the strategy...
9.
Greenwood M, Seftel M, Richardson C, Barbaric D, Barnett M, Bruyere H, et al.
Leuk Lymphoma
. 2006 Aug;
47(7):1245-52.
PMID: 16923553
Acute myeloid leukemia (AML) presenting with a high leukocyte count has been associated with an increase in induction mortality and poor results in a number of other survival measures. However,...
10.
Savoie M, Nevil T, Song K, Forrest D, Hogge D, Nantel S, et al.
Ann Oncol
. 2006 Feb;
17(5):763-8.
PMID: 16497826
Background: We assessed the feasibility of outpatient chemotherapy and supportive care in patients with acute myeloid leukemia (AML). Patients And Methods: All patients receiving curative intent chemotherapy between 09/01 and...